

the American Association for Cancer Research, March 1998.)

Pyrazoles can be prepared by methods described in WO 95/15,316. Pyrozoles can further be prepared by methods described in WO 95/15315. Pyrozoles can also be prepared by methods described in WO 96/03385. Thiophene analogs can be prepared by methods described in WO 95/00501. Preparation of thiophene analogs is also described in WO 94/15932. Oxazoles can be prepared by the methods described in WO 95/00501. Preparation of oxazoles is also described in WO 94/27980. Isoxazoles can be prepared by the methods described in WO 96/25405. Imidazoles can be prepared by the methods described in WO 96/03388. Preparation of imidazoles is also described in WO 96/03387. Cyclopentene cyclooxygenase-2 inhibitors can be prepared by the methods described in U.S. Patent No. 5,344,991. Preparation of cyclopentane Cox-2 inhibitors is also described in WO 95/00501. Terphenyl compounds can be prepared by the methods described in WO 96/16934. Thiazole compounds can be prepared by the methods described in WO 96/03,392. Pyridine compounds can be prepared by the methods described in WO 96/03392. Preparation of pyridine compounds is also described in WO 96/24,585.

Nonlimiting examples of COX-2 inhibitors that may be used in the present invention are identified in Table 1 below.

Table No. 1. Cyclooxygenase-2 Inhibitors

| Compound | Trade/ Research Name | Reference | Dosage |
|---|-------------------------|---|--------|
| 1,5-Diphenyl-3-substituted pyrazoles | | WO 97/13755 | |
| | radicicol | WO 96/25928. Kwon et al (Cancer Res (1992) 52 6296) | |
| | GB-02283745 | | |
| | TP-72 | Cancer Res 1998 58 4 717 -723 | |
| 1-(4-chlorobenzoyl)-3-[4-(4-fluorophenyl)thiazol-2-ylmethyl]-5-methoxy-2-methylindole | A-183827.0 | | |
| | GR-253035 | | |
| 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide | JTE-522 | JP 9052882 | |
| 5-chloro-3-(4-(methylsulfonyl)p | | | |

| Compound | Trade/ Research Name | Reference | Dosage |
|---|-------------------------|--|----------------|
| henyl)-2-(methyl- 5-pyridinyl)- pyridine | | | |
| 2-(3,5-difluoro- phenyl)-3-4- (methylsulfonyl)- phenyl)-2- cyclopenten-1-one | | | |
| | L-768277 | | |
| | L-783003 | | |
| | MK-966; VIOXX® | US 5968974 | 12.5-100 mg po |
| indomethacin- derived indolalkanoic acid | | WO 96/374679 | 200 mg/kg/day |
| 1-Methylsulfonyl- 4-[1,1-dimethyl- 4-(4- fluorophenyl)cycl openta-2,4-dien- 3-yl]benzene | | WO 95/30656. WO 95/30652. WO 96/38418. WO 96/38442. | |
| 4,4-dimethyl-2- phenyl-3-[4- (methylsulfonyl)p henyl]cyclo- butenone | | | |
| 2-(4- methoxyphenyl)-4- | | EP 799823 | |